Co-Diagnostics, Inc. (CODX) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-05-14

Key Insights

Co-Diagnostics announced Q1 2026 financial results on May 14, 2026, with the detailed press release furnished as Exhibit 99.1 but not formally filed, limiting the extent of liability associated with the disclosure.
The filing indicates the company is a small business issuer trading on Nasdaq Capital Market under ticker CODX, suggesting a smaller-cap diagnostics company that may face liquidity or analyst coverage constraints.
The 8-K was signed by CFO Brian Brown as the principal financial officer, indicating standard earnings announcement procedures with no indication of material agreements, leadership changes, or extraordinary events that would typically drive stock movement.

Want the newest filings?

This analysis covers the filing from 2026-05-14. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-03-31

Co-Diagnostics reported financial results for the year ended December 31, 2025, providing investors with updated information on the company's performance.
The company did not disclose any details on revenue, margins, or guidance, limiting the ability to assess the financial health and future prospects.
Without substantive information on the company's operations and outlook, investors have limited visibility into the current state and trajectory of the business.

Filed: 2026-01-13

Co-Diagnostics, Inc. has been notified by Nasdaq that its common stock will be delisted from the Nasdaq Capital Market due to its failure to meet the minimum bid price requirement of $1.00 per share.
The company plans to request a hearing before the Nasdaq Hearings Panel to address the bid price deficiency, but its shares will be suspended from trading on Nasdaq effective January 14, 2026.
The company's shares will likely trade on the Pink Limited Information tier of the OTC Market under the current trading symbol 'CODX' after the suspension.

Filed: 2025-12-30

Co-Diagnostics, Inc. announced a 1-for-30 reverse stock split effective January 1, 2026, which should help the stock meet Nasdaq's minimum share price requirement and maintain its exchange listing.
The reverse split will reduce the number of outstanding shares from approximately 62.8 million to around 2.1 million, potentially improving trading liquidity and visibility for investors.
The company's press release indicates there will be no changes to the rights or preferences of the common stock as a result of the reverse split.

Other reports for Co-Diagnostics, Inc.

Quarterly Report Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.